Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $5.9 million.

  • Stoke Therapeutics' Accounts Payables rose 13625.75% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 13625.75%. This contributed to the annual value of $2.5 million for FY2024, which is 4737.46% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Accounts Payables of $5.9 million as of Q3 2025, which was up 13625.75% from $4.3 million recorded in Q2 2025.
  • Stoke Therapeutics' Accounts Payables' 5-year high stood at $5.9 million during Q3 2025, with a 5-year trough of $766000.0 in Q4 2022.
  • Moreover, its 4-year median value for Accounts Payables was $2.5 million (2024), whereas its average is $2.9 million.
  • Per our database at Business Quant, Stoke Therapeutics' Accounts Payables crashed by 5680.18% in 2023 and then skyrocketed by 15353.47% in 2024.
  • Stoke Therapeutics' Accounts Payables (Quarter) stood at $766000.0 in 2022, then surged by 121.28% to $1.7 million in 2023, then surged by 47.37% to $2.5 million in 2024, then skyrocketed by 135.03% to $5.9 million in 2025.
  • Its Accounts Payables stands at $5.9 million for Q3 2025, versus $4.3 million for Q2 2025 and $2.2 million for Q1 2025.